- Report
- April 2025
- 93 Pages
Global
From €5343EUR$5,850USD£4,569GBP
- Report
- March 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- March 2025
- 200 Pages
Global
From €4101EUR$4,490USD£3,507GBP
- Report
- May 2024
- 137 Pages
Global
From €5936EUR$6,499USD£5,076GBP
- Report
- September 2024
- 343 Pages
Global
From €7261EUR$7,950USD£6,209GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2740EUR$3,000USD£2,343GBP
- Report
- January 2023
- 85 Pages
Europe
From €1370EUR$1,500USD£1,172GBP
- Report
- January 2024
- 156 Pages
United States
€3471EUR$3,800USD£2,968GBP
- Report
- January 2024
- 114 Pages
United States
€3197EUR$3,500USD£2,734GBP
- Report
- January 2024
- 109 Pages
United States
€3197EUR$3,500USD£2,734GBP
- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
Ipratropium is a medication used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both oral and inhaled forms, and is often used in combination with other medications to treat respiratory conditions. Ipratropium is also used to treat acute exacerbations of COPD, and is sometimes used to treat acute asthma attacks.
Ipratropium is a generic drug, meaning it is available from multiple manufacturers. Some of the companies that produce and market ipratropium include GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceuticals, and Mylan. Show Less Read more
